Investigational Drug Information for Ibudilast
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Ibudilast?
Ibudilast is an investigational drug.
There have been 21 clinical trials for Ibudilast.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2020.
The most common disease conditions in clinical trials are Alcoholism, Alcohol Drinking, and Sclerosis. The leading clinical trial sponsors are MediciNova, University of California, Los Angeles, and National Institute on Drug Abuse (NIDA).
There are eight hundred and eight US patents protecting this investigational drug and seven international patents.
Summary for Ibudilast
| US Patents | 808 |
| International Patents | 7,921 |
| US Patent Applications | 3,638 |
| WIPO Patent Applications | 1,401 |
| Japanese Patent Applications | 1,308 |
| Clinical Trial Progress | Phase 2 (2020-12-01) |
| Vendors | 98 |
Recent Clinical Trials for Ibudilast
| Title | Sponsor | Phase |
|---|---|---|
| A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder | University of Pennsylvania | Phase 2 |
| Canadian Adaptive Platform Trial for Long COVID | University Health Network, Toronto | Phase 2/Phase 3 |
| Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS | MediciNova | Phase 2 |
Clinical Trial Summary for Ibudilast
Top disease conditions for Ibudilast
Top clinical trial sponsors for Ibudilast
US Patents for Ibudilast
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ibudilast | See Plans and Pricing | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | See Plans and Pricing |
| Ibudilast | See Plans and Pricing | Therapeutic approaches for treating Parkinson's disease | Pharnext (Issy les Moulineaux, FR) | See Plans and Pricing |
| Ibudilast | See Plans and Pricing | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | See Plans and Pricing |
| Ibudilast | See Plans and Pricing | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag | The Catholic University of America (Washington, DC) | See Plans and Pricing |
| Ibudilast | See Plans and Pricing | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ibudilast
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ibudilast | Canada | CA2961033 | 2034-09-11 | See Plans and Pricing |
| Ibudilast | European Patent Office | EP3192791 | 2034-09-11 | See Plans and Pricing |
| Ibudilast | Japan | JPWO2016039408 | 2034-09-11 | See Plans and Pricing |
| Ibudilast | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | See Plans and Pricing |
| Ibudilast | Australia | AU2012222348 | 2031-03-01 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
